| BackgroundPancreatic cancer is a highly invasive tumors of the digestive tract, the onset hidden, which is often in middle-late when diagnosed clearly, and the cure rate is extremely low, the 5-year survival rate is only 1-4%, with poor prognosis. Its diagnostic markers such as CA19-9, although is recognized as the most valuable marker to diagnose pancreatic cancer now, but its value is embodied in treatment of pancreatic cancer. It has been diagnosed patients on the detection and selection of surgery and prognosis judgement, etc. Because of the high malignant degree, and the means of clinical diagnosis and treatment of the effects which are not good, we urgently need to develop new methods of treatment for the tumor. With the development of molecular biology theory and technology in this field, to explore the pathogenesis of pancreatic cancer and to explore new diagnosis and treatment becoming a hotspot in recent period. according to new research study,a pancreatic cancer progression has experienced more than 20 years at least. if you can give the early diagnosis of pancreatic cancer befor clinical effect, and early intervention on the growth, it will likely to be fundamentally make the treatment and prognosis of pancreatic cancer a certain degree of change. Former literatures reported that many kinds of tumor markers will be used for the diagnosis of pancreatic cancer, its specificity and sensitivity are not very ideal, especially for early diagnosis of less significance.At present, early diagnosis of pancreatic cancer related research, is mainly focused on pancreatic cancer tumor markers and the study of molecular biology. For gene chip technology, we can undertake polygenic joint detection, can provide a new direction in diagnosis of gene; Also can be quickly and efficiently analyze gene expression in pancreatic cancer specimens which have potential value.]so as to get the value in the diagnosis of disease, prognosis and treatment plan formulation.Along with the understanding of malignant tumor, more and more the domestic and foreign researchers found the miRNA(tiny RNA) is a kind of small molecules. it is closely associated with the occurrence and development of a wide variety of tumor. In recent years, researchers pay more and more attention to the study of non-coding RNA, found the miRNA is a kind of very important noncoding RNA. miRNAs is composed by size about 21-23 bases of single small molecules which is composed of Dicer enzyme processing single-stranded RNA and it is a single-stranded RNA consists of about 70-90 bases hairpin structure. Lin- 4 and let- 7 is the earliest discovered micrornas, found in c. elegans in the early, then also gradually found and identified hundreds of micrornas in fruit flies, plants, humans and other creatures. In the process of research, we found that the miRNA and tumor is closely related to the occurrence and development. A large number of studies have shown that the way of regulating target genes is inhibite or degradate the target genes of micrornas.It involved in regulating many kinds of biological signaling pathways. It confirmed that Micrornas involved in regulating various cellular processes including metabolism, hematopoietic cell differentiation, cell apoptosis, and the nervous system, and even the invasion and metastasis of tumor. At present, more and more studies have shaown that the miRNA plays a crucial role in the occurrence and development of tumor. therefore to seek a high sensitivity and specificity tumor maker will have a significant meaning in the judgment of the early diagnosis and prognosis of pancreatic cancer. And researching the expression of miRNA in pancreatic cancer will offer an important information in the diagnosis of the tumor, the recognize of disease prognosis for high risk and low risk, the prevention of cancer and providing important information to predict treatment response.a lot of Study found that miR216 a plays an important role in gastric cancer, breast cancer and prostate cancer, but less research in pancreatic cancer. a study suggests that miR216 a belongs to tumor suppressor genes in pancreatic cancer.This study focuses on verifying the expression and clinic significance of miR216 a and its target gene JAK2, CSK in pancreatic cancer and tissue adjacent to carcinoma.AimDetecting the expression of miR216 a and its target JAK2?CSK in pancreatic cancer and normal paraffin embedding tissues adjacent to carcinoma,and arguing the relationship between them.MethodsCollecting 45 cases of the pancreatic cancer tissues paraffin embeded from first affiliated hospital of zhengzhou university in March 2011 to November 2014 undergo surgical resection and collect the 45 cases of normal tissue adjacent to carcinoma in comparison. 3 um thickness of the slice, HE staining, histologic diagnosis of pancreatic ductal adenocarcinoma, all cases of preoperative put did not receive chemotherapy. Locked nucleic acid in situ hybridization method was developed to detect the expression of miR216 a and immune histochemical method to detect the expression of its target JAK2?CSK in pancreatic cancer and normal paraffin embedding tissues adjacent to carcinoma,and And analyze the correlation between the three, and their respective relations with the clinical indicators of pancreatic cancer. Using SPSS17.0 for the statistical analysis, apply Spearman correlation analysis, to test the relationship among miR216 a, JAK2 and CSK. inspection level(a = 0.05, P < 0.05) for the difference is statistically significant.ReasultsLocked nucleic acid in situ hybridization method shows that miR216 a positive staining was blue, positioning in the cytoplasm or nucleus, are weakly positive in pancreatic cancer tissue(figure ABC). the positive expression rate of miR216 a in pancreatic cancer tissue was 37.8%(17/45), and 71.1%(32/45) in normal tissue adjacent to carcinoma, the difference is statistically significant(c2= 10.080, P<0.05). Immunohistochemical method was used to show the JAK2 protein staining were localized in the cytoplasm and positive staining for brownish yellow or brown(Figure DEF), the positive expression rate of JAK2 protein in pancreatic cancer tissues, cancer adjacent normal tissue was 60%(27 / 45), 35.6%(16 / 45); the difference has statistical significance(r= 5.388, P < 0.05). Immunohistochemistry staining showed that CSK protein staining were localized in the cytoplasm and positive staining for brownish yellow or brown(Figure GHI), the positive expression rate of JAK2 in pancreatic cancer tissues and its adjacent normal tissues were 17.8%(which it is), 73.3%(33 / 45), the difference is statistically significant(r= 27.999, P < 0.05).The expression levels of miR216 a has a relationship with Pancreatic Cancer TNM stage, and patient gender, age, tumor differentiation degree, local lymph node metastasis, distant metastasis(P > 0.05); The expression levels of JAK2 protein, CSK protein have a relationship with the degree of differentiation of pancreatic cancer, and patients' age, gender, TNM staging, local lymph node metastasis, distant metastasis is not(P > 0.05). The expression of MiR216 a has nothing to do with the patient's gender, age, degree of differentiation, portal vein or abdominal nerve invasion, lymph node metastasis or not. JAK2 in high, medium and low differentiation of pancreatic cancer cells positive expression rate was 20%(1/5), 68.9%(20/29),and 68.9%(9/11).The positive expression rate of CSK in high, medium and low differentiation of pancreatic cancer cells was 80%(4/5), 20.7%(6/29), 27.2%(3/11), the differences were statistically significant( P < 0.05). JAK2, CSK and pancreatic cancer in patients with sex, age, TNM stage, portal vein or abdominal nerve invasion, lymph node metastasis or not has nothing to do.3 spearman correlation analysis showed that miR216 a expression level in pancreatic cancer tissue is negatively correlated with JAK2(r = 0.436, P < 0.05);the expression level of miR216 a in pancreatic cancer tissue was positively related with CSK(r = 0.223, P < 0.05), positive correlation between expression of JAK2 and CSK in pancreatic cancer tissue(r = 0.443, P < 0.05).ConclusionmiR216 a expressed in pancreatic cancer tissue is down-regulated, JAK2 expression in pancreatic cancer tissue is up- regulated, and CSK expressed in pancreatic cancer tissue is down-regulated, miR216 a may be playing a Incidence of inhibition by regulating the expression of JAK2 and CSK in pancreatic cancer. |
PDF Full Text Request